Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023.
作者信息
Mann Laura M, Zhu Weiming, Huang Ya-Lin A, Kourtis Athena P, Fanfair Robyn Neblett, Hoover Karen W
机构信息
National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
JAMA. 2024 Nov 12;332(18):1580-1583. doi: 10.1001/jama.2024.21493.
Abstract
摘要
相似文献
1
Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023.2013 - 2023年美国口服和注射用HIV暴露前预防药物处方趋势
JAMA. 2024 Nov 12;332(18):1580-1583. doi: 10.1001/jama.2024.21493.
2
Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.卡博特韦：首款长效抗 HIV 暴露前预防注射剂。
Ann Pharmacother. 2023 Mar;57(3):306-316. doi: 10.1177/10600280221102532. Epub 2022 Jul 1.
3
Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study.美国男男性行为者对每日、按需和长效注射型 HIV 暴露前预防用药的偏好（2021-2022 年）：全国范围在线横断面研究。
JMIR Public Health Surveill. 2024 Nov 13;10:e62801. doi: 10.2196/62801.
4
Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy.注射吸毒者对用于阿片类物质使用障碍、暴露前预防和抗逆转录病毒治疗的长效药物的看法。
Open Forum Infect Dis. 2025 Mar 6;12(3):ofaf120. doi: 10.1093/ofid/ofaf120. eCollection 2025 Mar.
5
Clinic-based interventions to increase preexposure prophylaxis awareness and uptake among United States patients attending an obstetrics and gynecology clinic in Baltimore, Maryland.基于诊所的干预措施，以提高在美国马里兰州巴尔的摩的妇产科诊所就诊的患者对暴露前预防措施的认识和接受度。
Am J Obstet Gynecol. 2023 Oct;229(4):423.e1-423.e8. doi: 10.1016/j.ajog.2023.07.046. Epub 2023 Jul 31.
6
Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S.美国黑人女性对 HIV 暴露前预防产品的偏好
AIDS Behav. 2022 Jul;26(7):2212-2223. doi: 10.1007/s10461-021-03571-8. Epub 2022 Jan 5.
7
Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.长效注射用卡替拉韦用于性少数和性别少数群体的 HIV 暴露前预防：一项实施研究方案。
JMIR Public Health Surveill. 2023 Apr 19;9:e44961. doi: 10.2196/44961.
8
Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States.实现 HIV 不一致夫妇的安全受孕：口服暴露前预防（PrEP）在美国的潜在作用。
Am J Obstet Gynecol. 2011 Jun;204(6):488.e1-8. doi: 10.1016/j.ajog.2011.02.026. Epub 2011 Mar 31.
9
Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension.在乌干达和肯尼亚的农村地区使用卡替拉韦长效注射剂进行动态选择艾滋病毒预防：一项随机试验扩展。
Lancet HIV. 2024 Nov;11(11):e736-e745. doi: 10.1016/S2352-3018(24)00235-2. Epub 2024 Oct 9.
10
Brief communication: attitudes and preferences of long-acting injectable HIV preexposure prophylaxis among Thai adolescents and young adults.简短通讯：泰国青少年和青年中长效注射用艾滋病病毒暴露前预防的态度和偏好
AIDS Res Ther. 2025 Mar 2;22(1):28. doi: 10.1186/s12981-025-00721-z.
引用本文的文献
1
"The Simplest Way to Go": An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP.“最简便的途径”：探究注射毒品的女性选择长效注射用卡博特韦而非每日口服暴露前预防药物的原因
AIDS Behav. 2025 Aug 6. doi: 10.1007/s10461-025-04833-5.
2
Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.来那卡帕韦：如果能公平应用，它可能会改变美洲地区艾滋病预防的格局。
Lancet Reg Health Am. 2025 Jun 10;47:101146. doi: 10.1016/j.lana.2025.101146. eCollection 2025 Jul.
3
Real-world HIV RNA and antigen/antibody testing among people who use long-acting injectable PrEP.使用长效注射用暴露前预防药物人群的真实世界HIV RNA及抗原/抗体检测
Clin Infect Dis. 2025 Apr 3. doi: 10.1093/cid/ciaf173.
4
Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.长效注射用卡博特韦在美国南部一家安全网医院初级保健中心用于预防HIV感染的早期实施情况。
J Gen Intern Med. 2025 Feb 11. doi: 10.1007/s11606-025-09350-8.
5
Why is roll-out of long-acting PrEP agents so slow?长效暴露前预防药物的推广为何如此缓慢？
Curr Opin HIV AIDS. 2025 Jan 1;20(1):48-53. doi: 10.1097/COH.0000000000000899. Epub 2024 Nov 14.
6
Long-acting preexposure prophylaxis: early data on roll-out in the United States.长效暴露前预防：美国推广的早期数据。
Curr Opin HIV AIDS. 2025 Jan 1;20(1):25-31. doi: 10.1097/COH.0000000000000894. Epub 2024 Nov 5.
本文引用的文献
1
National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 : A Retrospective Cohort Study.美国 2014 至 2018 年艾滋病毒暴露前预防药物支付的全国趋势：一项回顾性队列研究。
Ann Intern Med. 2020 Nov 17;173(10):799-805. doi: 10.7326/M20-0786. Epub 2020 Sep 8.
2
Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.利用 2016 年 7 月至 2018 年 6 月来自纽约市的参考人群评估用于 PrEP 监测的算法。
Public Health Rep. 2020 Mar/Apr;135(2):202-210. doi: 10.1177/0033354920904085. Epub 2020 Feb 6.
3
HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.HIV 暴露前预防，按种族和族裔划分-美国，2014-2016 年。
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150. doi: 10.15585/mmwr.mm6741a3.
Zotero 插件